Abstract
Objective
The aim of this study was to evaluate the impact of FDG-PET in the management of patients with salivary gland malignancy.
Patients and Methods
We performed 45 FDG PET studies in 31 patients with salivary malignant tumors, using PET (33 studies) and PET/CT (12 studies). Patients comprised 21 males and 10 females with a mean age of 69 y (range 38–89). Nineteen patients had a single study, ten patients had 2 and two patients had 3 studies. Twelve studies were performed for initial staging and 33 studies for restaging. Four patients of the initial staging group were restaged with PET after therapy. Histology consisted of 8 adenocarcinomas, 8 squamous cell carcinomas, 4 adenoid cystic carcinomas, 4 carcinoma ex pleomorphic adenomas, 2 mucoepidermoid carcinomas, 2 poorly differentiated carcinomas, 1 salivary duct carcinoma, 1 lymphoepithelial carcinoma and 1 melanoma. PET findings were reviewed with the clinical and radiologic findings and the impact of PET on staging and patient management was determined.
Results
In the initial staging group, all 12 primary lesions (100%) showed positive FDG uptake (5 squamous cell carcinomas, 2 adenocarcinomas, 2 poorly differentiated carcinomas, 1 carcinoma ex pleomorphic adenoma, 1 salivary duct carcinoma, 1 lymphoepithelial carcinoma). Three patients (25%) had FDG positive distant disease (liver, bone, lymph nodes); surgery was canceled and therapy changed to chemoradiation. One patient (9%) with no FDG uptake in the neck nodes avoided a planned neck dissection. In the restaging group (33 studies in 23 patients), 5 patients (22%) had FDG positive distant disease, which changed the treatment from surgery to chemoradiation or other. A second primary lesion was detected in one patient (4%). One patient (4%) with clinically suspected recurrence was able to avoid other invasive procedures because of the negative PET. Overall, FDG PET resulted in a major change in management in 11 of 31 patients (35%).
Conclusion
This study shows that FDG PET has a significant impact on the management of patients with salivary malignant tumors in both the initial staging and restaging.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Reference
Schoder H, Yeung HWD, Gonen M, Larson SM. Head and Neck Cancer: Clinical Usefulness and Accuracy of PET/CT Image Fusion.Radiology 2004; 231: 65–72.
Teknos TN, Rosenthal EL, Lee D, Taylor R, Marn CS. Positron emission tomography in the evaluation of stage III and IV head and neck cancer.Head Neck 2001; 23: 1056–1060.
Nakamoto Y, Tatsumi M, Hammoud D, Cohade C, Osman MM, Wahl RL. Normal FDG distribution patterns in the head and neck: PET/CT evaluation.Radiology 2005; 234: 879–885.
Keyes JW Jr, Harkness BA, Greven KM, Williams DW 3rd, Watson NE Jr, McGuirt WF. Salivary gland tumors: pretherapy evaluation with PET.Radiology 1994; 192: 99–102.
Okamura T, Kawabe J, Koyama K, Ochi H, Yamada R, Sakamoto H, et al. Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Imaging of Parotid Mass Lesions.Acta Otolaryngol 1998; 538: 209–213.
Uchida Y, Minoshima S, Kawata T, Motoori K, Nakano K, Kazama T, et al. Diagnostic value of FDG PET and salivary gland scintigraphy for parotid tumors.Clin Nucl Med 2005; 30: 170–176.
Yoshikai T, Ishimaru J, Satoh T, Inokuchi A, Kudo S. The limitations of gallium scintigraphy in the differentiation between benign and malignant salivary gland mass lesions.Nucl Med Commun 2003; 24: 657–662.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Graham, M.M., Otsuka, H., Kogame, M. et al. The impact of FDG-PET in the management of patients with salivary gland malignancy. Ann Nucl Med 19, 691–694 (2005). https://doi.org/10.1007/BF02985118
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02985118